A best-practice position statement on pregnancy after kidney transplantation: focusing on the unsolved questions. The Kidney and Pregnancy Study Group of the Italian Society of Nephrology

Gianfranca Cabiddu1 · Donatella Spotti2 · Giuseppe Gernone3 · Domenico Santoro4 · Gabriella Moroni5 · Gina Gregorini6 · Franca Giacchino7 · Rossella Attini8 · Monica Limardo9 · Linda Gammaro10 · Tullia Todros8 · Giorgina Barbara Piccoli11,12 on behalf of The Kidney and Pregnancy Study Group of the Italian Society of Nephrology

Received: 22 February 2018 / Accepted: 30 April 2018 / Published online: 14 June 2018
© The Author(s) 2018, corrected publication July/2018

Abstract

Kidney transplantation (KT) is often considered to be the method best able to restore fertility in a woman with chronic kidney disease (CKD). However, pregnancies in KT are not devoid of risks (in particular prematurity, small for gestational age babies, and the hypertensive disorders of pregnancy). An ideal profile of the potential KT mother includes “normal” or “good” kidney function (usually defined as glomerular filtration rate, GFR ≥ 60 ml/min), scant or no proteinuria (usually defined as below 500 mg/dl), normal or well controlled blood pressure (one drug only and no sign of end-organ damage), no recent acute rejection, good compliance and low-dose immunosuppression, without the use of potentially teratogen drugs (mycophenolic acid and m-Tor inhibitors) and an interval of at least 1–2 years after transplantation. In this setting, there is little if any risk of worsening of the kidney function. Less is known about how to manage “non-ideal” situations, such as a pregnancy a short time after KT, or one in the context of hypertension or a failing kidney. The aim of this position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology is to review the literature and discuss what is known about the clinical management of CKD after KT, with particular attention to women who start a pregnancy in non-ideal conditions. While the experience in such cases is limited, the risks of worsening the renal function are probably higher in cases with markedly reduced kidney function, and in the presence of proteinuria. Well-controlled hypertension alone seems less relevant for outcomes, even if its effect is probably multiplicative if combined with low GFR and proteinuria. As in other settings of kidney disease, superimposed preeclampsia (PE) is differently defined and this impairs calculating its real incidence. No specific difference between non-teratogen immunosuppressive drugs has been shown, but calcineurin inhibitors have been associated with foetal growth restriction and low birth weight. The clinical choices in cases at high risk for malformations or kidney function impairment (pregnancies under mycophenolic acid or with severe kidney-function impairment) require merging clinical and ethical approaches in which, beside the mother and child dyad, the grafted kidney is a crucial “third element”.

Keywords Chronic kidney disease · Evidence-based medicine · Pregnancy · Hypertension · Proteinuria · Preeclampsia · Pre-term delivery

Introduction: an historical note

The history of pregnancy after kidney transplantation starts with young twin sisters: “In May, 1956, one of a pair of 21-year-old identical twin females from Oklahoma was being studied as a potential recipient for a kidney transplant from her twin sister”. It is interesting to note that in this paper the family status was reported in the opening sentences: “Both were childless, having been married for less...
than a year.” The state of the recipient was defined as “dire” “with hypertension (blood pressure of 190 systolic, 120 diastolic), congestive heart failure (…)” [1].

The paper reports that this woman regained her health, recovered her menstrual cycle and soon became pregnant, giving birth, by caesarean section, chosen for fear of renal compression, to a healthy baby. The donor and recipient were enthusiastic enough to give birth, as the paper reports, to a total of five babies, all of them in good health, at the time The New England Journal of Medicine paper was published [1].

In 1966, Murray et al. wrote in JAMA: “Medical advances force new judgments and evaluations. The ethics, legality, and morality of organ transplantation, a recent and still unpredictable therapeutic procedure, has already elicited editorials, special articles, and conferences (…)”, underlining the importance of maintaining what we now call quality of life, which was implicit in the job of a good physician, before measurement was attempted.

In this context it is worth quoting the paper entitled “Transplantation and haemodialysis. The recipient’s response to renal transplantation”, in which we read: “I guess, like other people, I never fully appreciated the simple things in life until I lost them. Just to be able to get up in the morning and go out and do a day’s work is a wonderful feeling (…)” [2].

When Edith Helm died, 55 years after having transplantation, leaving a son, a daughter, four grandchildren and four great-grandchildren, Professor Murray, who considered the sisters and their families part of “the extended Murray family”, thanked her for her contribution to demonstrating that having a child after transplantation was possible. Besides eliciting admiration for the Nobel Prize winner, this story should also teach us the importance of curiosity and humility, and of personalised solutions in the management of pregnancy after kidney transplantation [3]. Not many years would pass before there were reports of successful pregnancies after transplantation from non-identical twins and of vaginal deliveries [4, 5]. The era of pregnancy after kidney transplantation had begun [6–8].

**Evidence-based medicine and pregnancy after KT: methodological insights**

Evaluating the evidence on pregnancy in kidney transplantation (KT) is dogged by many of the same methodological problems as that on pregnancy in chronic kidney disease (CKD) or in patients on dialysis [9–16]. A common language is lacking, in particular for the definition of preeclampsia (PE), and for preterm delivery. The population is highly heterogeneous, and relatively few large studies are available; the periods of study are different and stratification is seldom attempted. Information on miscarriages is scant, and is usually limited to small single-centre series, due to the difficulties inherent in tracking the data on larger series or registries [17–26]. Hence, most systematic reviews and large series conclude by stating that more evidence is needed, and while we have data on “ideal patients”, less is known about patients with reduced kidney function, disease recurrence or proteinuria.

After kidney transplantation, as in all the CKD stages, the degree of kidney impairment, hypertension and proteinuria are acknowledged factors in the pathogenesis of adverse pregnancy-related outcomes, even though their pathogenesis is incompletely understood [27–32].

Kidney function assessment in pregnancy is a challenge both after KT and in CKD: no validated formula exists and stratifications based upon serum creatinine, or serum cystatin-C are not commonly employed [33–43]. Because there are so few randomized controlled trials (RCTs) and large observational studies, we will deal mainly with low levels of recommendation and not graded suggestions, so that in this paper we present what constitutes “best practice”, underlining the key role experience plays in supporting clinical choices [9, 10].

**Evidence-based medicine and pregnancy after KT: bioethical aspects**

(i) Pregnancy is not a “zero-risk” choice. Grading the risks of pregnancy after kidney transplantation is difficult, in particular in cases that differ from the “ideal” candidate (strong suggestion, evidence from different sources, mainly epidemiological studies).

(ii) Pregnancy after KT poses important ethical problems (strong suggestion, beyond evidence).

(iii) Pregnancy in “non-ideal” candidates after KT is an example of bioethical conflict, in which the principles of ethical assessment may give rise to contrasting evaluations (strong suggestion, beyond evidence).

Pregnancy is not a “zero-risk” situation: in the general population, more than 10% of pregnancies are complicated by hypertensive disorders (including 3–5% of PE) or by gestational diabetes [44–47]. All these events are more common in CKD, starting in its early stages, and this also applies to KT patients with normal kidney function [32, 48–51].

In the absence of a precise quantification of the risks across the scale of kidney function and proteinuria, it is difficult to define what an “acceptable risk” is for a pregnancy after KT [52–54]. In fact, with the excellent results of the first pregnancies after KT pregnancy became an option that gave rise to great expectations—the conviction that restoring fertility after a successful KT would be possible in a not too
distant future [1, 2, 4–6, 55]. As will be discussed below, the ideal candidate for pregnancy after KT is a woman with normal kidney function, no proteinuria, normotension, no recent acute rejection, good compliance and low dose immunosuppression, who has not taken potentially teratogen drugs [mycophenolic acid and mammalian target of rapamycin (m-Tor) inhibitors] in the last months, and after at least 1–2 years after transplantation.

One of the main issues in this context is the definition of “normal” or “good” kidney function: the classic CKD classification is not routinely used after kidney transplantation, and studies use different cut-points as for definition of normal or good kidney function [17–26].

There is no doubt that a glomerular filtration rate (GFR) above 90 ml/min defines a normal renal function; “good” renal function is usually defined as a GFR above 60 ml/min, even if, at least according to the Italian experience, there may be significant differences between patients with GFR ≥ 90 ml/min and those with 60–90 ml/min of GFR [56].

Likewise, the definition of the cut-points for proteinuria and hypertension are non-univocal; while there is no doubt that, as well as in the overall population, blood pressure level below 130/80 is optimal and proteinuria in pregnancy is considered as normal when below 300 mg/day, there is a grey zone for blood pressure level below 140/90 and proteinuria below 300–500 mg/day [17–26, 56].

The Study Group therefore proposes an individualised evaluation in all cases with GFR (at best assessed by creatinine clearance) below 90 ml/min, blood pressure above 130/80 mmHg and proteinuria above 300 mg/day.

The literature reports few cases of pregnancy in the context of malfunctioning KT, suggesting that counselling has systematically discouraged pregnancies in “less than ideal” conditions; therefore, risk assessment in a “failing” KT is presently difficult. Even if not quantified, these situations constitute a risk of developing severe hypertension, proteinuria and prematurity, and of accelerating kidney failure [6–8, 32]. Hence, in the presence of strong determination to have a baby, the clinical decision must merge with an ethical approach.

Pregnancy in the context of “less than ideal” KT is an example of conflict between four main principles of medical ethics (autonomy, non-maleficence, beneficence, and justice). The benefit for a KT woman of having a baby is clear, and conflicts with the potential harm to the kidney graft, to maternal health and to the baby, who risks being born preterm, with potential consequences for its long-term health. None of these risks is however clearly quantifiable.

The concept of distributive justice, that considers KT as a resource in contrast with decisions that could accelerate its loss, while ensuring the patient’s autonomy means that the final choice cannot be taken by a third party [55–59].

The hierarchy of ethical principles differs from one country to another. In Mediterranean countries, where the patient-physician relationship historically followed a paternalist model, the principle of *primum non nocere* supported the negative medical attitude towards pregnancy in less-than-optimal conditions. Conversely, in English-speaking countries, where the patient’s self-determination is seen as paramount, autonomy comes first, and it is felt that it should be respected after ensuring that the patient has comprehended and accepted the risks her decision involves. The practice, observed in some transplant centres, of asking the patients to avoid pregnancy, as a way to optimize the social advantage of a successful transplantation, considers justice to be the leading principle [60–68].

There is no “right answer” in bioethics. However, the current ethical approaches, under the influence of Anglo-American bioethics, privilege autonomy, a concept that is increasingly integrated in juridical recommendations. The paradigm shift from paternalism to self-determination and from non-maleficence to autonomy will probably lead to a more permissive attitude towards pregnancy after KT in less than optimal conditions.

**What are the main adverse outcomes in pregnancy in KT patients?**

(i) The risk of maternal death is low and difficult to quantify (strong suggestion; scattered evidence).

(ii) The risks of worsening kidney function are low in KT patients with normal kidney function, but have not been clearly quantified in other cases (moderate suggestion; scattered evidence).

(iii) The risks to the foetus are mainly related to prematurity (strong suggestion; evidence from large observational studies and registries).

(iv) Foetal malformations do not increase in KT patients, if teratogen drugs are avoided (strong suggestion, large body of evidence from different sources).

(v) There is no substantial difference in outcomes between patients treated with non-teratogen drugs; calcineurin inhibitors may be associated with risk of foetal growth restriction (strong suggestion; indirect evidence from different sources).

(vi) The risk of adverse maternal-foetal outcomes appears to be higher in multiple pregnancies (moderate suggestion, few available data).

(vii) The risk of adverse maternal-foetal outcomes appears to be higher in assisted-fertilization pregnancies (moderate suggestion, few available data).
Maternal death is rare enough to represent a non-quantifiable risk during or immediately after a KT pregnancy. The long-term risks are difficult to quantify and should probably be discussed in relation to pregnancy when counselling dialysis patients [16, 69–73].

The risk of kidney function impairment is low in KT patients who start pregnancy with normal kidney function. The definition of normal kidney function is however not univocal, and is often based on creatinine levels and not on creatinine clearance or GFR [38, 39, 43].

As will be discussed below, the risks are higher in patients with reduced kidney function; this should be obvious considering the progressive impairment of the results seen in non-KT patients with CKD [13, 28, 30, 74–76].

New onset of proteinuria or increase of pre-existing proteinuria seems to be common; once more, the lack of standard criteria and the low use of 24-h proteinuria after KT make it difficult to assess the evidence [77].

Prematurity (defined as birth before 37 completed gestational weeks), early preterm delivery (before 34 completed gestational weeks) and extremely preterm delivery (before 28 gestational weeks) increase in KT pregnancies and the increase is greater in KT patients with impaired kidney function. No graduation of the effect across stages is yet available.

Among the many risks linked to prematurity that should be addressed in counselling (perinatal death, retinopathy, and neurological problems) the possibility that premature babies are more likely to develop CKD and hypertension or cardiovascular diseases in adulthood should be discussed [78–94].

There is no evidence that children from KT mothers have a higher rate of malformations than the general population, except for those linked to genetic diseases, such as congenital abnormalities of the kidneys and of the urinary tract (CAKUT) or autosomal dominant polycystic kidney disease (ADPKD) [17–21, 23, 56, 95–100].

Data on CKD and the general population suggest that multiple pregnancies have higher risks of adverse outcomes [9, 101–105]. This should be kept in mind, especially for women receiving assisted-reproduction treatment, which is becoming increasingly popular with KT patients, and in turn creates a higher risk of adverse pregnancy-related outcomes [106–109].

Few studies have been specifically addressed to the long-term health of the children of KT mothers. Based on the scant evidence available, it appears that most children of KT mothers attain normal developmental goals. However, the neurological problems linked to prematurity should not be underestimated and must be explained at counselling [73, 78–94, 110–113]. The Study Group feels there is a clear need for further long-term studies focussing on the psychosocial health of these children and on their intellectual development.

Which patients are the “best candidates” for pregnancy after KT and which patients are not?

(i) The following are the requirements most often cited for identifying the best candidates for pregnancy after KT from the clinical point of view:

(a) Normal or good kidney function (differently defined: usually as above 60 ml/min)
(b) No proteinuria or scarce proteinuria (differently defined: usually as below 300–500 mg/day)
(c) No hypertension or well-controlled hypertension (the latter usually defined as treated in monotherapy and without organ damage)
(d) Low-dose immunosuppression with “allowed” drugs
(e) At least 2 years after KT (this interval has recently been reduced to 1 year after KT) (strong suggestion, several sources of observational data).

(ii) Further clinical maternal elements that can contribute to identifying the “best candidates” include:

(a) No recent rejection episode
(b) No recurrent urinary tract infection
(c) Discontinuation of potentially teratogen drugs for at least 6 weeks (moderate suggestion, several sources of observational data and indirect evidence).

(iii) From the obstetric point of view, besides the absence of hypertension, and kidney disease, a low-risk mother is young (under 35), non-obese, non-diabetic, with a spontaneous singleton pregnancy (strong suggestion, several sources of observational data and indirect evidence).

(iv) All other cases are high-risk KT pregnancies. No graduation of risks is presently available (strong suggestion, several sources of observational data and indirect evidence).

Identification of the best candidates for pregnancy after KT is based on the results of observational studies [17, 32]. Overall, KT pregnancy risks display behaviours similar to those found in CKD pregnancies, and the best results are in patients with normal kidney function, normotension and no proteinuria [9, 17, 30, 32, 51, 56, 114–120].
On account of its patients’ characteristics, the transplant world has remained impermeable to the CKD staging system and the definition of “normal” kidney function is usually based upon serum creatinine, with different cut-points in different studies. The relationship between kidney function and pregnancy outcomes is not surprising, and is probably the first item to take into account in a risk assessment. However, no graduation of risks is available and the Study Group suggests, in the absence of new data, applying the same criteria that have proven to be efficacious in CKD (stratification along the classic CKD stages) [9, 11, 30, 56, 121].

Hypertension and proteinuria are identified as independent risk factors for adverse pregnancy outcomes [30]. However, as no study has tested their combined effect, the Study Group suggests basing counselling on the wider set of data on CKD pregnancies, in which the presence of hypertension and proteinuria exert a multiplicative effect on the risks. KT patients with hypertension and proteinuria should therefore be informed of the high incidence of preterm delivery in CKD patients with both hypertension and proteinuria, even in those with normal or near normal kidney function [30, 50, 122].

Immunologic stability is another must. This includes being rejection-free for at least 6 months (some studies do not define the interval and in others the length of time ranges from 6 months to 1–2 years), and being treated with low-dose immunosuppression. There were several studies that indicated that pregnancy was safer at least 2 years after KT; however, recent studies suggest that waiting for 1 year can lead to superimposable results [123–128]. A few reports of pregnancies immediately after KT or of KT during the early weeks of pregnancy indicate that success is also possible in these cases, warning against systematic pregnancy termination in such occurrences [129, 130].

As previously stated, a GFR above 90 ml/min, a blood pressure at or below 130/80 mmHg and proteinuria inferior to 300 mg/dl clearly defines an ideal situation. A grey area includes GFR 60–90 ml/min, blood pressure below 140/90 mmHg and proteinuria below 500 mg/day [17–26, 56].

The Study Group therefore proposes an individualised evaluation in all these cases.

The relationship between acute rejection and pregnancy is complex. This is a situation which calls to mind the relationship between pregnancy and flares in systemic lupus erythematosus: in the past flares were considered frequent, while when they were subsequently re-dimensional, this led to abandoning the policy of administering bolus steroids at or immediately after delivery [9, 131].

A pregnant grafted woman has been defined as a complex chimera with at least three cell populations: her own ones, the donor organ, and the foetus. Previous pregnancies and blood transfusions may have added other cell populations. The tolerance system is complex and not all antigens induce a response; tolerance may be the result of exposure of particular antigens or complexes [132].

The postpartum period is also of pivotal importance: the acute loss of the placenta, which was a primary driver of tolerance, could theoretically trigger rejection, while the decrease of interleukin (IL)-10 and estrogen levels may counterbalance this effect [132, 133]. Acute kidney injury (AKI) is a relatively unexplored syndrome post-partum, and new data suggest in particular to pay attention to the use of anti-fibrinolytic agents [134].

While recent epidemiological studies are reassuring concerning the risk of rejection, the Study Group feels it is vital to take into account the clinical impression that acute rejection during pregnancy or in puerperium can be particularly aggressive. While more experience-based than evidence-based, this consideration should suggest maintaining a high level of attention in these delicate moments of a woman’s life [17, 23, 24, 26].

Urinary tract infections are frequent in KT pregnancies; once more, the recent literature is scant. However, considering the experience in CKD pregnancies, the Study Group suggests maintaining a policy of high attention, and performing a urinary culture at least twice monthly, as counselled for CKD women with a history of upper urinary tract infections, kidney malformations or kidney scars [9, 135, 136].

Table 1 shows the main immunosuppressive drugs employed in pregnant KT patients. Azathioprine, cyclosporine, tacrolimus and steroids are considered safe [137–154]. Little is known about m-Tor inhibitors, but since they are teratogen in animals, they are avoided in humans, even if a few cases with a positive outcome have been recently reported in the literature [137–139]. Since mycophenolate can cause a characteristic embryopathy, known as MMF foetal syndrome, this drug should be discontinued at least 6 weeks before conception [123, 125, 140–152].

While several studies focus on the effect of kidney function on pregnancy outcomes, less is known on the additive effect of the classical risk factors on KT pregnancies [153].

High maternal age increases the risk for preterm delivery and PE. Obesity is associated with a higher risk of the hypertensive disorders of pregnancy; the same is true for diabetes, which is also associated with congenital malformations, often at the cardiac level [17, 49, 154–156]. The risks are higher in type-1 diabetic mothers. The effect of assisted fertilization and multiple pregnancies, also associated with adverse pregnancy outcomes, will be further discussed below [157–159].

Acknowledging these knowledge gaps, the Study Group underlines the need for further studies targeting pregnancies in “non-ideal” KT pregnancies.
**Frequency and modality of controls in KT pregnancy**

Follow-up should be intensified in KT patients as compared with normal pregnancies (strong recommendation, indirect evidence)

The main goals of follow-up are early identification and treatment of complications, including acute rejection, hypertension, anaemia, coagulation disorders, and timely planning of delivery (strong recommendation, indirect evidence)

No validated formula for GFR calculation in KT pregnancy is available, hence GFR should be assessed by 24-h urine collection (strong recommendation, based on GFR in normal pregnancy and PE)

By analogy with follow-up in pre-RRT CKD stages, follow-up should be intensified in KT patients with reduced kidney function, hypertension and proteinuria (strong recommendation, indirect evidence)

Follow-up should include at least one nephrology consultation with blood and urinary tests every 2–4 weeks in non-proteinuric, non-hypertensive KT patients with “good” kidney function; the frequency of controls should be increased in the case of proteinuria, hypertension or reduced kidney function (strong recommendation, indirect evidence)

Pregnancy after KT should be considered as “at high risk”, even in the presence of the “ideal” profiles delineated above, and the Study Group suggests increasing the frequency of controls in proportion to the decrease in kidney function, based on the presence of hypertension, proteinuria, urinary tract infection or any other risk factor; particular attention should be paid to the side effects of antirejection therapies (Table 1).

The flow charts, adapted from the position statement on CKD and pregnancy, summarize the proposed frequency of controls (Fig. 1) [9].

The Study Group suggests a minimum requirement of one nephrology control with blood and urinary tests every 2–4 weeks in patients with “good” kidney function (in the absence of clear definitions, we consider this group to be women with at least 60 ml/min of creatinine clearance measured on 24-h urine collection), and without proteinuria and hypertension, increasing to weekly controls in patients with any combination of the risk factors mentioned above.

The assessment of kidney function is especially challenging in KT pregnancies. Little is known about the role of

---

**Table 1** Main immunosuppressive drugs for chronic treatment in pregnant KT patients (modified from reference [9])

| Drug                      | Main features                                                                 | FDA rating |
|---------------------------|-------------------------------------------------------------------------------|------------|
| Azathioprine              | This is the most widely used immunosuppressive drug. It is teratogen in animal models, but not in humans, possibly because the foetal liver is not able to activate the drug. KDIGO and European Best Practice Guidelines suggest switching from mycophenolate to azathioprine before pregnancy | D          |
| Cyclosporine A            | This calcineurin inhibitor has not been associated with increased teratogenicity; however, small for gestational age babies and preterm delivery have been reported, possibly due to the maternal disease and not specifically to the drug. Levels may vary in pregnancy and the hypertensive, hyperglycaemic and nephrotoxic effects should be mentioned | C          |
| Tacrolimus                | The drug has similar effects and side effects to cyclosporine A; experience is more limited than with the previous drug | C          |
| Steroids                  | Together with azathioprine these are the most often employed and best known drugs. The most frequently used short-acting corticosteroids include prednisone, methylprednisolone and prednisolone, while betamethasone and dexamethasone are among the long-acting drugs. No major malformations have been reported, and the issue of labiopalatoschisis is debated. A higher risk of premature rupture of membranes has been reported. Other relevant side effects include infectious risk, and the increased risk of gestational diabetes | C          |
| Mycophenolate             | Severe foetal malformations are reported, mainly involving cardiovascular and cranial malformations. Discontinuation for at least 6 weeks, to stabilize kidney function, is usually indicated after kidney transplantation | D          |
| m-Tor inhibitors          | Very few studies have considered their use in pregnancy. They are teratogenic in animals and discontinuation in humans is a matter of debate. KDIGO guidelines suggest discontinuation in anticipation of pregnancy | C          |
| Rituximab, simulect        | Too few studies to allow safe use in pregnancy. Need for further evidence, but trials are unlikely to be undertaken | C, D       |

FDA rating [135]: A, controlled human studies show no risk; B, no evidence of risk in studies; C, risk cannot be ruled out; D, positive evidence of risk; X, contraindicated in pregnancy

KT kidney transplantation, FDA US Food & Drug Administration, KDIGO kidney disease-improving global outcomes
hyperfiltration, an increase in plasma volume and in volume distribution; validated GFR formulae are not available (a problem shared by all CKD stages), and creatinine clearance on 24-h urine collection is not frequently employed; similar considerations apply to proteinuria [160, 161]. Therefore, in the absence of agreed assessments, the Study Group considers it wise to refer to the same gold standard identified for CKD patients (based on 24-h urine collection for both creatinine clearance and proteinuria).

An important issue is probably also the presence of the physiological decrease or of an increase of serum creatinine in pregnancy. Once more, there are no specific data in this regard, but according to the clinical experience the Study group underlines the importance of paying attention to the presence-absence of physiological increase in the kidney function as a potential predictive element of pregnancy outcomes after KT.

The issue of an increase in extracellular volume is important and is probably one of the reasons for the frequent need to increase doses of the calcineurin inhibitors. The higher need for anti-rejection drugs is probably multifactorial as many patients need to at least double the initial doses prescribed, despite the fact that distribution volume is usually only about 30% higher (Table 1).

KT patients are at risk for urinary tract infections; therefore, urinalysis and urinary cultures should be a part of routine controls, and the frequency should be increased to weekly in patients with recurrent urinary tract infections during or before pregnancy (Fig. 1).

These considerations balance time-consuming assessments (24-h urine collection, frequent urine and/or blood tests) with the need for close control of the mother, foetus and grafted kidney, using simple, non-invasive procedures. The Study Group underlines that these recommendations are based mainly on scattered evidence and common clinical understanding. Further economic evaluations and organisational analyses are highly recommended.
Treatment of hypertension in KT pregnancy

Pre-existing hypertension should be managed like chronic hypertension in CKD women, with careful monitoring, avoiding overcorrection (strong recommendation, indirect evidence and scattered data).

Hypertension occurring in pregnancy, with or without proteinuria, should be differentiated from PE, on account of the different prognosis for the two conditions in pregnancy (moderate recommendation, indirect evidence and scattered data).

Low-dose acetylsalicylic acid can be employed in the prevention of PE, in patients without contraindications, as in other high-risk pregnancies (moderate recommendation, indirect evidence and scattered data).

Blood pressure targets in hypertensive KT pregnancies have not been established, similarly to what was observed in CKD pregnancies [9, 13]. Learning from data available on pregnancies in chronic hypertension, overcorrection should be avoided, given its detrimental effects on foetal growth [162–171].

In keeping with the indications for CKD pregnancies, on the basis of the results of the large Control of Hypertension In Pregnancy Study (CHIPS) trial, our group suggests implementing strict blood pressure control (“ideal” target < 130/80 mmHg, acceptable < 140/90 mmHg), under careful clinical surveillance [9, 168].

As reported in Table 2, no anti-hypertensive drug is labelled as fully safe in pregnancy. Most importantly, the teratogenicity of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) is still a matter of debate; therefore, the Study Group strongly supports pre-emptive discontinuation of ACEi and ARBs in patients without proteinuria, and early discontinuation at the first positive pregnancy test (4th–6th gestational week) in patients in whom proteinuria is considered a potential threat for kidney function [9, 171–176].

The differential diagnosis between hypertension and proteinuria due to recurrence of the original disease, chronic allograft nephropathy or reduced nephron mass and PE is clinically important, since the maternal-foetal prognosis is worse in the latter [177–179].

Uric acid levels are well known markers of risk of adverse pregnancy outcomes in pregnancies in the overall population; there are limited data after kidney transplantation, suggesting that low pre-conception uric acid levels are correlated with positive pregnancy outcomes, but their role as

Table 2 Commonly needed drugs in pregnant patients with kidney transplantation (modified from reference [9])

| Drug               | Anti-hypertensives                                                                 | FDA rating   |
|--------------------|------------------------------------------------------------------------------------|--------------|
| Usually considered first choice                                                                 |
| Alpha-methyl dopa  | Widely used, with no reported negative effects on the foetus or on its subsequent development. May not be able to correct severe hypertension | B            |
| Niphedipine        | The long-acting drug most commonly used in pregnancy. The increase in peripheral oedema may be a relevant side effect in CKD patients | C            |
| Labetalole         | Usually well tolerated, should be avoided in subjects with asthma. In a RCT it was shown to be comparable to alpha-methyldopa | C            |
| Usually considered second choice                                                                 |
| Beta blockers      | The main drawback was foetal growth restriction. Atenolol (D) often involved. May be effective in severe hypertension. May induce hypoglycaemia, hypotension and bradycardia at delivery | B Pindolol  |
| Clonidine          | Side effects and rebounds at discontinuation are common. Slowing foetal growth also reported | C Metoprolol|
| Alpha blockers     | Other drugs should be preferred since controlled studies are missing               | C            |
| Diuretics          | Usually avoided. Thiazides may be continued. Amiloride may be employed in Gitelman syndrome | B Hydrochlorothiazide Amiloride |
| To be avoided                                                                 |
| Short-acting niphedipine | Contraindicated by FDA, RCOG and AIPE due to the risk of severe sudden hypotension with detrimental effects on placental flows | D            |
| ACEi ARBs          | Risk of major malformations, in particular in the second and third trimester        | C 1st trimester, D 2nd 3rd trimester |

FDA rating: A, controlled human studies show no risk; B, no evidence of risk in studies; C, risk cannot be ruled out; D, positive evidence of risk; X, contraindicated in pregnancy

RCOG Royal College of Obstetricians and Gynaecologists, AIPE Associazione Italiana Preeclampsia, ACEi angiotensin-converting enzyme inhibitors, ARBs angiotensin II receptor blockers. For other abbreviations, see Table 1
bimarkers is not confirmed after kidney transplantation [180]. Among the biomarkers of PE, the ratio between soluble Fms-like tyrosine kinase 1 (sFlt-1), a receptor for both vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) is of high interest at least in ruling out the severe forms of PE [181–184]. The role of these biomarkers in the differential diagnosis between PE and CKD is still under study, and the Study Group recommends using the test, when available, in support of clinical reasoning [9].

**Management of proteinuria in KT pregnancy**

Evidence on pregnancy in KT patients with proteinuria is limited, hence the main suggestions are derived from the broader experience with CKD patients (medium recommendation, indirect evidence)

- Low-dose acetyl salicylate is indicated in proteinuric patients (as well as in patients with reduced kidney function or hypertension) (strong recommendation, different levels of evidence in various diseases)

- Efforts should be made to counterbalance hyperfiltration: while albumin infusion should be avoided, moderate protein restriction can be attempted (medium recommendation, indirect evidence)

- Low-dose acetyl salicylate (ASA) for the prevention of PE is suggested by a large body of evidence; all KT patients share an increased risk of PE, higher in patients with proteinuria or hypertension [185–193]. The best timing for starting ASA is debated; the Study Group suggests that ASA should be continued in pregnancy if already part of the chronic treatment. In the case of ASA start, early start (at positive test) to favour placentation or later start (2nd trimester) to minimise bleeding risks in the case of miscarriage, should be discussed within the multidisciplinary team [9].

- Two recent meta-analyses suggest that early ASA use (start before 16 weeks) is associated with better outcomes, but the dose is different in the two studies and the effect is only significant as for prevention of early PE, which is probably less frequent in transplanted, as well as CKD women, than “late-maternal” PE [192, 193].

- Due to the pathophysiological importance of hyperfiltration in long-term kidney damage, the Study Group suggests avoiding, whenever possible, treatments which potentially increase hyperfiltration, such as albumin infusion [194].

- Although we lack robust evidence on the advantages of a moderate protein restriction, often suggested in other forms of CKD, the Study Group recommends avoiding protein-rich diets, and considering the potential of this nutritional approach at least in cases in which hyperfiltration is thought to play an important role, in keeping with what is advised in CKD [9, 195, 196].

**Management of KT pregnancy with reduced kidney function**

Evidence on pregnancy in KT patients with reduced kidney function is scant, probably as a result of the policy of discouraging pregnancy in this context (medium recommendation, indirect evidence)

- Given the lack of data grading the effect of reduced kidney function in KT pregnancy, counselling and management should be based on the experience in CKD (strong recommendation, indirect evidence).

- There is no indication on when to start dialysis in pregnancy in the setting of a failing KT. This knowledge gap should be considered in counselling (strong recommendation, indirect evidence).

- Evidence on pregnancy when there is a failing KT is extremely limited, differently from the growing body of evidence on pregnancy in the most advanced CKD stages in native kidneys. The most likely explanation is that this is an indirect effect of discouraging pregnancy in “less than optimal” conditions after KT [197].

- As previously discussed from the bioethical point of view, the growing importance attributed to patients’ autonomy will probably modify this situation, but our lack of data makes precise counselling difficult, and points to basing advice upon the larger body of data available on native kidneys. In this regard, the Study Group would like to refer to the previous “best practice” on pregnancy in CKD [9].

- A particular aspect, not fully clarified even in non-pregnant KT patients, regards when to restart dialysis in a failing KT. Bearing in mind this lack of evidence and acknowledging the experience in the non-pregnant population and the most recent guidelines, the Study Group suggests adopting individualised policies, based upon clinical judgement and not on GFR only, in agreement with what was previously discussed in CKD [9].

**Management of inadvertent pregnancy under potentially teratogen agents, or undertaken “too early”**

The most important potentially teratogen agent employed after KT is mycophenolate mofetil (MMF), whose use is associated with severe malformations, mainly skeletal and ocular ones, and with mental retardation (strong recommendation, scattered data)

- The severity of the syndrome is variable and MMF treatment is also compatible with apparently normal development. The reasons for the syndrome’s different presentation are not known (strong recommendation, scattered data).
Physicians of women under MMF should be aware that they need to interrupt treatment at least 6 weeks before a patient becomes pregnant (strong recommendation, scattered data).

Other potentially teratogen drugs (m-TOR inhibitors, ACEi and ARBs) have less clear risk patterns and probably have a lower incidence of malformations (strong recommendation, scattered data).

The issue of pregnancy occurring “too early” merges the frequent use of contraindicated drugs and higher immunological risks (strong recommendation, scattered data).

The caregiver multidisciplinary team should support the patient’s choice to continue or terminate pregnancy, offering careful counselling and making use of imaging to detect major foetal abnormalities (strong recommendation, indirect data).

When pregnancy is undertaken early in the course of transplantation or is unexpected, the use of drugs that are contraindicated (such as MMF), or for which there is a reasonable doubt of teratogenicity (such as ACEi, ARBs and m-TOR inhibitors), poses clinical and ethical problems. The issue of timing for discontinuation before elective pregnancy is still open; consensus is now on discontinuation of MMF and enteric coated mycophenolate sodium (EC-MPS) at least 6 weeks before attempting conception; m-TOR inhibitors should also be discontinued or replaced before pregnancy is attempted, even if positive reports are available (Table 1).

The most important problem occurs when pregnancy is unexpected and conception has occurred while the patient was on these treatments; in fact, none of these drugs is a cause of malformations in 100% of cases, thus leaving space for individual choice. While ultrasounds are increasingly able to detect major skeletal and organ malformations, some relevant malformation is not detectable, or is first seen in phases in which pregnancy interruption is no longer possible [198].

In the absence of potentially teratogen drugs, the classic contraindication to pregnancy in the first 2 years after renal transplantation is based upon the clinical assumption that the risk of acute rejection, graft dysfunction, and infection are higher than in the subsequent period. The empiric limit of 2 years has recently been challenged, suggesting that outcomes may level after the first year of KT, thus widening the “ideal” timing, also taking into account that kidney function is usually better in the first years after kidney transplantation [125, 126].

In this regard, the Study Group suggests that conception should be avoided in the first year after KT. The best contraception treatment is still a matter of debate and a further best-practice paper will be dedicated to this issue. In the lack of evidence, the Study Group suggests a tailored approach be adopted, taking age, kidney function, risk of infection, renal disease and coagulation derangements into account [128, 199–203].

In the case of “early” conception, i.e. in the first year after KT, in the absence of teratogen drugs, the Study Group does not support a policy of systematic pregnancy interruption, but once more suggests a personalised policy that considers the increased risk of graft dysfunction, and the likelihood of there being a further pregnancy in a “safer” period, based on considerations such as the patient’s age and, if possible, information on her ovarian reserve.

**Management of KT patients with multiple gestations**

Multiple gestations, whether spontaneous or occurring as a result of assisted fertilization procedures, are at higher risk for adverse pregnancy-related outcomes (strong recommendation, indirect data).

There are few data on multiple pregnancies after KT and the ones we have are probably affected by reporting and publication biases. Within these limits, it seems that good outcomes are possible and may be the rule (medium recommendation, indirect data).

There is no need to interrupt multiple-gestation pregnancy in KT; however, follow-up should be intensified and an expert on the clinical management of multiple gestations should be included in the team (strong recommendation, indirect data).

In the general population, multiple gestations, whether spontaneous or occurring as a result of assisted fertilization procedures, are at higher risk for adverse outcomes [101, 157–159]. A similar increase in risk has been described in pregnancies occurring in CKD patients, although the amount of data is limited, and there is probably a reporting and publication bias, leading to over reporting of favourable outcomes with respect to unfavourable ones. The current evidence only allows us to state that good outcomes are possible and may even be the rule, thus indicating that there is no reason for pregnancy termination in “ideal candidates”. However, follow-up should be intensified and an expert on the clinical management of multiple gestations should be included in the team. Patients in less than ideal situations should be warned both about the absence of elements allowing precise risk assessment, and the fact that outcomes are less favourable in multiple pregnancies, whether or not these have resulted from assisted fertilization procedures [101–103, 105].

**Advising KT patients who want to undergo assisted fertilization procedures**

Assisted fertilization in the general population has a higher risk of PE, intrauterine growth restriction, and prematurity (strong recommendation, observational data).
Assisted fertilization procedures are feasible in KT patients, but the evidence is scant and affected by reporting and publication biases. Within these limits, good outcomes are reported virtually with all techniques, but the incidence of adverse events is not known (strong recommendation, indirect data).

In the case of pregnancy after assisted fertilization techniques, follow-up should be intensified and experts should be included in the team (strong recommendation, indirect data).

Assisted fertilization is increasingly chosen in the general population, to overcome the limits imposed by age and chronic diseases. All these techniques are associated with higher risk of PE, intrauterine growth restriction, and prematurity; the risks increase with the need for in vitro manoeuvres, reaching a peak for egg donation. According to an increasing number of reports, mainly based on single cases, assisted fertilization procedures are feasible in KT patients, but the evidence is scant and there are likely to be important reporting and publication biases, leading to over-reporting of successful cases [106–108]. Within these limits, good outcomes after KT are reported when using virtually all techniques, but the incidence of adverse events is not quantifiable on the basis of the present state of evidence, as only one relatively large series was found by our extensive search strategy [108].

Since assisted fertilization techniques are associated with a significant increase in adverse events in the general population, the Study Group urges that follow-up be intensified and experts in the field be included in the multidisciplinary team in KT pregnancy after assisted fertilization.

While, given the present state of the art, the Study Group does not feel that nephrologists should encourage or discourage these procedures, our position is that while we support the choice of the mother-to-be, we should counsel techniques that are more likely to lead to a single rather than to a multiple pregnancy. Due to the complexity of this problem, the Study Group plans to discuss it in a further dedicated best-practice review.

**Pregnancy in kidney-pancreas transplantation: specific issues**

Solid-organ-transplant recipients should be considered high-risk patients for pregnancy (strong recommendation, indirect data).

In pancreas-kidney transplantation (PKT) the presence of two organs in the pelvis poses additional risk to both mother and newborn (strong recommendation, indirect data).

The pancreas graft probably presents fewer complications during pregnancy in the presence of normoglycaemia (medium recommendation, scant data).

Birth weight and gestational age are usually lower when compared to KT (strong recommendation, registry data).

An integrated multidisciplinary team including a transplant physician, nephrologist, diabetologist, and obstetrician is essential in counselling and follow-up (strong recommendation, indirect data).

In the case of PKT, as in all solid-organ transplantation, recipients should be considered high-risk for pregnancy and management should be carried out by a multidisciplinary team, including a diabetologist, even in the presence of normal glycaemic levels. In fact, in PKT recipients the presence of two organs in the pelvis poses an additional risk to both mother and newborn [8, 204]. The risks are miscarriage, preterm birth, foetal malformation, preeclampsia, deterioration of renal function, and pancreatitis of the graft, reported even after uncomplicated delivery [205–207].

The pancreas graft probably presents fewer complications during pregnancy in the presence of normoglycaemia and, as in all cases of solid-organ transplantation, the risks are reduced if the pregnancy is planned, and if the organs are functional. As in the case of KT, the suggested timing is at least 1 year after transplantation with normal blood pressure, absent proteinuria and stable doses of immunosuppressive drugs.

Registry data indicate that mean birth weight and gestational age are lower when compared to kidney-only recipients, but the reasons for this are still a matter of debate [207].

For these reasons, the Study Group suggests that pregnant PKT mothers should be monitored very closely, indicatively every 2 weeks, during pregnancy. A fully integrated multidisciplinary team, including a transplant physician, nephrologist, diabetologist, and obstetrician is essential for counselling and in the follow-up of PKT pregnancy.

**Working conclusions**

Pregnancy is an added value for women with kidney transplantation; fertility is at least partly restored and a successful pregnancy is possible, frequent, and usually successful. However, KT pregnancies have a higher risk of PE, preterm delivery and small for gestational age babies than pregnancies in the general population.

The profile of the “best” candidate for pregnancy after KT is relatively well drawn (normal or “good” kidney function, usually considered as a GFR above 60 ml/min), normotension or well controlled hypertension (one drug only, in the absence of end-organ damage), no proteinuria (or proteinuria below 300–500 mg/day), no recent rejection episode, and conception at least 1 year after KT. Definitions are however not always univocal, and less is known about “non-ideal” candidates, who pose important clinical and ethical
problems in the complex interaction between the “best choice” for the mother, for the child and for kidney function.

Thanks to the progress in KT therapies, to improvements in the management of high-risk pregnancies, to the growing importance of patients’ self-determination, and to new options, such as assisted fertilization, the panorama of pregnancy after KT is changing.

The side effect of this positive outlook is that evidence is heterogeneous and sometimes difficult to interpret. This lack of certitudes should be borne in mind at counselling, and strongly supports shared choices in the context of multidisciplinary care, as well as individualised approaches. Nephrologists need continuous updating in this emerging field, and once more the Study Group supports the establishment of educational programs and of multicentre research studies.

Acknowledgements  To Susan Finnel for her careful language review. The Italian Study group on Kidney and Pregnancy thanks the Centre Hospitalier Le Mans for the support in the language editing.

Funding  No funding was obtained for this position statement.

Compliance with ethical standards

Conflict of interest  None of the authors has any conflict of interest.

Ethical approval  No ethical committee approval is needed for the present position statement, performed on behalf of the Study Group on Kidney and Pregnancy, of the Italian Society of Nephrology.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Murray JE, Reid DE, Harrison JH, Merrill JP (1963) Successful pregnancies after human renal transplantation. N Engl J Med 269:341–343
2. Murray JE (1966) Transplantation and hemodialysis. I. The recipient’s response to renal transplantation. JAMA 198(3):305–306
3. Murray JE (2011) Edith Helm (April 29, 1935-April 4, 2011): the world’s longest surviving transplant recipient. Am J Transplant 11(7):1545–1546
4. Board JA, Lee HM, Draper DA, Hume DM (1967) Pregnancy following kidney homotransplantation from a non-twin. Report of a case with concurrent administration of azathioprine and prednisone. Obstet Gynecol 29(3):318–323
5. Kaufman JJ, Dignam W, Goodwin WE, Martin DC, Goldman R, Maxwell MH (1967) Successful, normal childbirth after kidney homotransplantation. JAMA 200(4):338–341
6. Hou S (2003) Pregnancy in renal transplant recipients. Adv Ren Replace Ther 10:40–47
7. Davison JM, Bailey DJ (2003) Pregnancy following renal transplantation. J Obstet Gynaecol Res 29:227–233
8. McKay DB, Josephson MA (2006) pregnancy in recipients of solid organs—effects on mother and child. N Engl J Med 354:1281–1293
9. Cabiddu G, Castellino S, Gernone G et al (2016) A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy. J Nephrol 29(3):277–303
10. Cabiddu G, Castellino S, Gernone G et al (2015) Best practices on pregnancy in dialysis: the Italian Study Group on Kidney and Pregnancy. Kidney and Pregnancy Study Group of Italian Society of Nephrology. J Nephrol 28(3):279–288
11. Piccoli GB, Cabiddu G, Attini R et al (2015) Pregnancy in chronic kidney disease: questions and answers in a changing panorama. Best Pract Res Clin Obstet Gynaecol 29(5):625–642
12. Nevis IF, Reitsma A, Dominic A et al (2011) Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol 6(11):2587–2598
13. Zhang JJ, Ma XX, Hao L, Liu LJ, Lv JC, Zhang H (2015) A Systematic review and meta-analysis of outcomes of pregnancy in CKD and CKD outcomes in pregnancy. Clin J Am Soc Nephrol 10(11):1964–1978
14. Alkhunaizi A, Melamed N, Hladunewich MA (2015) Pregnancy in advanced chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 24(3):252–259
15. Piccoli GB, Conijn A, Attini R, Biolcati M, Bossotti C, Consiglio V, Dragostini MC, Todros T (2011) Pregnancy in chronic kidney disease: need for a common language. J Nephrol 24(3):282–299
16. Piccoli GB, Minelli F, Versino E et al (2016) Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes. Nephrol Dial Transplant 31(11):1915–1934
17. Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Montgomery RA, Segev D (2011) Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant 11(11):2388–2404
18. Zachariah MS, Tornatore KM, Venuto RC (2009) Kidney transplantation and pregnancy. Curr Opin Organ Transplant 14(4):386–391
19. Armenti VT, Daller JA, Constantinescu S, Silva P, Radomski JS, Moritz MJ, Gaughan WJ, McGrory CH, Coscia LA (2006) Report from the National Transplantation Registry Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl 57–70
20. Hou S (1999) Pregnancy in chronic renal insufficiency and end stage renal disease. Am J Kidney Dis 33:235–252
21. Armenti VT (2011) Pregnancy after transplantation: milestones and assessments of risk. Am J Transplant 11:2275–2276
22. Levidiotis V, Chang S, McDonald S (2009) Pregnancy and maternal outcomes among kidney transplant recipients. J Am Soc Nephrol 20:2433–2440
23. McKay DB, Josephson MA (2008) Pregnancy after kidney transplantation. Clin J Am Soc Nephrol 3(Suppl 2):S117–S125
24. Bramham K, Nelson-Piercy C, Gao H, Pierce M, Bush N, Spark P, Brocklehurst P, Kurinczuk JJ, Knight M (2013) Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol 8:290–298
25. Wyld ML, Clayton PA, Jesudason S, Chadban SJ, Alexander SI (2013) Pregnancy outcomes for kidney transplant recipients. Am J Transplant 13(12):3173–3182
26. Richman K, Goh R (2012) Pregnancy after renal transplantation: a review of registry and single-center practices and outcomes. Nephrol Dial Transplant 27(9):3428–3434
27. Garovic VD (2000) Hypertension in pregnancy: diagnosis and treatment. Mayo Clin Proc 75(10):1071–1076
28. Piccoli GB, Fassio F, Attini R, Parisi S, Biocchi M, Ferraresi M et al (2012) Pregnancy in CKD: whom should we follow and why? Nephrol Dial Transplant 27(Suppl 3):iii11–iii118

29. Morikawa M, Yamada T, Minakami H (2009) Outcome of pregnancy in patients with isolated proteinuria. Curr Opin Obstet Gynecol 21(6):491–495

30. Piccoli GB, Cabiddu G, Attini R et al (2015) Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol 26(8):2011–2022

31. Fukasawa Y, Makino Y, Ogawa M, Uchida K, Matsui H (2016) Factors related to deterioration of renal function after singleton delivery in pregnant women with chronic kidney disease. Taiwan J Obstet Gynecol 55(2):166–170

32. You JY, Kim MK, Choi SJ, Oh SY, Kim SJ, Kim JH, Oh HY, Roh CR (2014) Predictive factors for adverse pregnancy outcomes after renal transplantation. Clin Transplant 28(6):699–706

33. Smith MC, Moran P, Ward MK, Davison JM (2008) Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG 115:109–112

34. Krutzén E, Olofsson P, Bäck SE, Nilsson-Ehle P (1992) Glomerular filtration rate in pregnancy: a study in normal subjects and in patients with hypertension, preeclampsia and diabetes. Scand J Clin Lab Invest 52:387–392

35. Ahmed SB, Bentley-Lewis R, Hollenberg NK et al (2009) A comparison of prediction equations for estimating glomerular filtration rate in pregnancy. Hypertens Pregnancy 28:243–255

36. Alper AB, Yi Y, Rahman M, Webber LS et al (2009) Performance of estimated glomerular filtration rate prediction equations in pre eclamptic patients. Am J Perinatol 26(8):425–439

37. Piccoli GB, Attini R, Vigotti FN et al (2015) Is renal hyperfiltration protective in chronic kidney disease-stage 1 pregnancies? A step forward unravelling the mystery of the effect of stage 1 chronic kidney disease on pregnancy outcomes. Nephrology (Carlton) 20(3):201–208

38. Luis-Lima S, Marrero-Miranda D, González-Rinne A, Torres A et al (2015) Estimated glomerular filtration rate in renal transplantation: the nephrologist in the mist. Transplantation 99(12):2625–2633

39. Al-Sehli R, Grebe S, Jacaj Z, Chen S, Li S, Craig K, Luyckx V, Mueller T (2015) What should the serum creatinine be after transplantation? An approach to integrate donor and recipient information to assess posttransplant kidney function. Transplantation 99(9):1960–1967

40. de Souza V, Cochat P, Rabilloud M, Selistre L, Wagner M, Hadi-Aissa A, Dolomanova O, Ranchin B, Iwaz J, Dubourg L (2015) Accuracy of different equations in estimating GFR in pediatric kidney transplant recipients. Clin J Am Soc Nephrol 10(3):463–470

41. Chrobak L, Dębska-Ślizień A, Jankowska M, Sledziński Z, Rutkowski P (2014) Epidemiology of posttransplantation chronic kidney disease can be altered by choice of formula estimating glomerular filtration rate. Transplant Proc 46(8):2660–2663

42. Harman G, Akbari A, Hiremath S, White CA, Ramsay T, Kokolo MB, Craig J, Knoll GA (2013) Accuracy of cystatin C-based estimates of glomerular filtration rate in kidney transplant recipients: a systematic review. Nephrol Dial Transplant 28(3):741–757

43. White CA1, Huang D, Akbari A, Garland J, Knoll GA (2008) Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review. Am J Kidney Dis 51(6):1005–1015

44. Lisonkova S, Joseph KS (2013) Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 209(6):544.e1–544.e12

45. Thornton C, Dahlen H, Korda A, Hennessy A (2013) The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000–2008. Am J Obstet Gynecol 205(6):476.e1–5

46. Auger N, Luo ZC, Nuyt AM, Kaufman JS, Naimi AI, Platt RW, Fraser WD (2016) Secular trends in preeclampsia incidence and outcomes in a large canada database: a longitudinal study over 24 years. Can J Cardiol 32(8):987.e15–23

47. Leeman L, Fontaine P (2008) Hypertensive disorders of pregnancy. Am Fam Physician 78(1):93–100

48. Piccoli GB, Cabiddu G, Attini R, Parisi S, Fassio F, Loi V, Gerbino M, Biocchi M, Panì A, Todros T (2016) Hypertension in CKD pregnancy: a question of cause and effect (cause or effect? this is the question). Curr Hypertens Rep 18(5):35

49. Brosens I, Brosens JJ, Benagiano G (2014) The risk of obstetrical syndromes after solid organ transplantation. Best Pract Res Clin Obstet Gynaecol 28(8):1211–1221

50. Rupley DM, Janda AM, Kapeles SR, Wilson TM, Berman D, Mathur AK (2014) Preconception counseling, fertility, and pregnancy complications after abdominal organ transplantation: a survey and cohort study of 532 recipients. Clin Transplant 28(9):937–945

51. Davison JM, Lindheimer MD (2011) Pregnancy and chronic kidney disease. Semin Nephrol 31:86–99

52. O’Leary CM, Bower C (2012) Guidelines for pregnancy: what’s an acceptable risk, and how is the evidence (finally) shaping up? Drug Alcohol Rev 31(2):170–183

53. Opel DJ, Taylor JA, Phillips CI, Diekema DS (2013) The intersection of evidence and values in clinical guidelines: who decides what constitutes acceptable risk in the care of children? Hosp Pediatr 3(2):87–91

54. David M, Gross MM, Wiemer A, Pachaly J, Vetter K (2009) Prior cesarean section—an acceptable risk for vaginal delivery at free-standing midwife-led birth centers? Results of the analysis of vaginal birth after cesarean section (VBAC) in German birth centers. Eur J Obstet Gynecol Reprod Biol 142(2):106–110

55. Murray JE, Lynch JH (1967) Ethical implications of renal transplants. JAMA 200(2):187

56. Piccoli GB, Cabiddu G, Attini R, Gerbino M, Todeschini P, Perino ML et al; Italian Study group on Kidney and Pregnancy of the Italian Society of Nephrology (2017) Working group on pregnancy in renal transplantation. Outcomes of pregnancies after kidney transplantation: lessons learned from CKD. A comparison of transplanted, nontransplanted chronic kidney disease patients and low-risk pregnancies: a multicenter nationwide analysis. Transplantation 101(10):2536–2544

57. Lockwood GM (1999) Pregnancy, autonomy and paternalism. J Med Philos 24(3):201–208

58. Pullman D (2005) Ethics first aid: reframing the role of “principlism” in clinical ethics education and practice. J Clin Ethics 16(3):223–229

59. McCarthy J (2003) Principlism or narrative ethics: must we choose between them? Med Humanit 29(2):65–71

60. McGrath P (1998) Autonomy, discourse, and power: a postmodern reflection on principlism and bioethics. J Med Philos 23(5):516–532

61. Gillon R (2003) Ethics needs principles—four can encompass the rest—and respect for autonomy should be “first among equals”. Med Law Rev 11:413–438

62. Page K (2012) The four principles: can they be measured and do they predict ethical decision making? BMC Med Ethics 13:10

63. Dawson A, Garrard E (2006) In defence of moral imperialism: four equal and universal prima facie principles. J Med Ethics 32(4):200–204

64. Tomkins A, Duff J, Fitzgibbon A, Karam A, Mills EJ, Munnings K, Smith S, Seshadri SR, Steinberg A, Vitullo R, Yugi P (2015) Controversies in faith and health care. Lancet 386:1776–1785
65. Grol-Prokopczyk H (2013) Thai and American doctors on medical ethics: religion, regulation, and moral reasoning across borders. Soc Sci Med 76(1):92–100
66. Westra AE, Willems DL, Smit BJ (2009) Communicating with Muslim parents: “the four principles” are not as culturally neutral as suggested. Eur J Pediatr 168(11):1383–1387
67. McCormick AJ (2013) Buddhist ethics and end-of-life care decisions. J Soc Work End Life Palliat Care 9(2–3):209–225
68. Ross LF (2006) Ethical considerations related to pregnancy in transplant recipients. N Engl J Med 354:1313–1316
69. Hou SH (1994) Pregnancy in women on haemodialysis and peritoneal dialysis. Baillieres Clin Obstet Gynaecol 8:481–500
70. Piccoli GB, Conijn A, Consiglio V et al (2010) Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy? Clin J Am Soc Nephrol 5:62–71
71. Toma H, Tanabe K, Tokumoto T, Kobayashi C, Yagisawa T (1999) Pregnancy in women receiving renal dialysis or transplantation in Japan: a nationwide survey. Nephrol Dial Transplant 14:1511–1156
72. Luders C, Castro MC, Titan SM et al (2010) Obstetric outcome in pregnant women on long-term dialysis: a case series. Am J Kidney Dis 56:77–85
73. Piccoli GB, Cabiddu G, Daidone G et al (2014) The children of dialysis: live-born babies from on-dialysis mothers in Italian epidemiological perspective comparing dialysis, kidney transplantation and the overall population. Nephrol Dial Transplant 29(8):1578–1586
74. Piccoli GB, Attini R, Vasario E et al (2010) Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol 5:844–855
75. Imbasciati E, Gregorini G, Cabiddu G et al (2007) Pregnancy in CKD stages 3–5: fetal and maternal outcomes. Am J Kidney Dis 49:753–762
76. Khedmat H, Alavian SM, Taheri S (2009) Pregnancy after renal transplantation: prospects and concerns. Ann Transplant 14(2):55–60
77. Wiles K, Ekbal N, Snowden S, Macphee I, Banerjee D (2006) Proteinuria in three sequential pregnancies following a fourth renal transplant. J Nephrol 19(6):828–830 (Erratum in: J Nephrol. 2009; 22(1):171)
78. Carmody JB, Charlton JR (2013) Short-term gestation, long-term risk: prematurity and chronic kidney disease. Pediatrics 131:1168–1179
79. Janvier A, Lorenz JM, Lants JD (2012) Antenatal counseling for parents facing an extremely preterm birth: limitations of the medical evidence. Acta Paediatr 101(8):800–804
80. Abitbol CL, Rodriguez MM (2012) The long-term renal and cardiovascular consequences of prematurity. Nat Rev Nephrol 8(5):265–274
81. Stelhoh C, Allen KP, Mattsson DL, Lerch-Gaggl A, Reddy S, El-Meanawy A (2012) Prematurity in mice leads to reduction in nephron number, hypertension, and proteinuria. Transl Res 159(2):80–89
82. Roggero P, Gianni ML, Garbarino F, Mosca F (2013) Consequences of prematurity on adult morbidities. Eur J Intern Med 24(7):624–626
83. Asano MK, Dray PB (2014) Retinopathy of prematurity. Dis Mon 60(6):282–291
84. Vohr B (2013) Long-term outcomes of moderately preterm, late preterm, and early term infants. Clin Perinatal 40(4):739–751
85. Sutherland MR, Bertagnoli M, Lukaszewski MA, Huyard F, Zydzorczyk C, Lui TM, Nuyt AM (2014) Preterm birth and hypertension risk: the oxidative stress paradigm. Hypertension 63(1):12–18
86. Kugelman A, Colín AA (2013) Late preterm infants: near term but still in a critical developmental time period. Pediatrics 132(4):741–751
87. Gubhaju L, Sutherland MR, Black MJ (2011) Preterm birth and the kidney: implications for long-term renal health. Reprod Sci 18:322–333
88. Sutherland MR, Gubhaju L, Moore L et al (2011) Accelerated maturation and abnormal morphology in the preterm neonatal kidney. J Am Soc Nephrol 22:1365–1374
89. Hodgin JB, Rasolpour M, Markowitz GS, D’Agati VD (2009) Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4:71–76
90. Luyckx VA, Brenner BM (2005) Low birth weight, nephron number, and kidney disease. Kidney Int Suppl 97:S68–S77
91. Luyckx VA, Brenner BM (2010) The clinical importance of nephron mass. J Am Soc Nephrol 21:898–910
92. Parkinson JR, Hyde MJ, Gale C, Santhakumar S, Modi N (2013) Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. Pediatrics 131(4):e1240–63
93. de Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB (2012) Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 59:226–234
94. Lohaugen GC et al (2013) Small for gestational age and intrauterine growth restriction decreases cognitive function in young adults. J Pediatr 163(2):447–453
95. North RA, Taylor RS, Gunn TR (2000) Pregnancy outcome in women with reflux nephropathy and the inheritance of vesicoureteric reflux. Aust N Z J Obstet Gynaecol 40(3):280–285
96. Jungers P, Houllier P, Chauveau D et al (1996) Pregnancy in women with reflux nephropathy. Kidney Int 50(2):593–599
97. Vora N, Perrone R, Bianchi DW (2008) Reproductive issues for adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 5:307–518
98. Chapman AB, Johnson AM, Gabow PA (1994) Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5(5):1178–1185
99. Wu M, Wang D, Zand L et al (2016) Pregnancy outcomes in autosomal dominant polycystic kidney disease: a case-control study. J Matern Fetal Neonatal Med 29(5):807–812
100. Banks N, Bryant J, Fischer R, Huizing M, Gahl WA, Gunay-Aygun M (2015) Pregnancy in autosomal recessive polycystic kidney disease. Arch Gynecol Obstet 291(3):705–708
101. Piccoli GB, Arduino S, Attini R et al (2013) Multiple pregnancies in CKD patients: an explosive mix. Clin J Am Soc Nephrol 8:41–50
102. Nicovani V, Poblote H, Toro J, Carrera M, Perez L (2009) Successful multiple pregnancy (triplets) in a kidney transplant recipient: a case report. Transplant Proc 41(6):2688–2690
103. Cheung CK, Bhandari S (2010) The effect of spontaneous twin pregnancy on renal transplant function and haemodynamics. NDT Plus 3(1):48–50
104. Farr A, Bader Y, Husslein PW, Gyori G, Muhlbacher F, Margreiter M (2014) Ultra-high-risk pregnancies in women after renal transplantation. Eur J Obstet Gynecol Reprod Biol 180:72–76
105. Gizzo S, Noventa M, Saccardi C, Paccagnella G, Patrelli TS, Cosmi E, D’Antona D (2014) Twin pregnancy after kidney transplantation: what’s on? A case report and review of literature. J Matern Fetal Neonatal Med 27(17):1816–1819
106. Khalaf Y, Elkening N, Anderson H, Taylor A, Braude P (2000) Ovarian hyperstimulation syndrome and its effect on renal function in a renal transplant patient undergoing IVF treatment: case report. Hum Reprod 15(6):1275–1277
107. Norrman E, Bergh C, Wennerholm UB (2015) Pregnancy outcome and long-term follow-up after in vitro fertilization in women with renal transplantation. Hum Reprod 30(1):205–213

108. Nouri K, Bader Y, Helmy S, Ott J, Jirecek S, Tempfer CB (2011) Live birth after in vitro fertilization and single embryo transfer in a kidney transplant patient: a case report and review of the literature. J Assist Reprod Genet 28(4):351–353

109. Muthuvel VA, Ravindran M, Chander A, Veluswamy C (2016) Successful pregnancy following single blastocyst transfer in a renal transplant recipient. J Hum Reprod Sci 9(1):53–55

110. Piccoli GB, Postorino V, Cabiddu G et al (2015) ‘Kidney and Pregnancy Study Group’ of the ‘Italian Society of Nephrology’. Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: a multicentre nationwide study 2000–12. Nephrol Dial Transplant 30(7):1193–1202

111. Abou-Jaoude P, Dubourg L, Bessenay L et al (2012) What about the renal function during childhood of children born from dialysed mothers? Nephrol Dial Transplant 27:2365–2369

112. Blowey DL, Warady BA (2007) Outcome of infants born to women with chronic kidney disease. Adv Chronic Kidney Dis 14:199–205

113. Banerjee I, Powis S, Shevlin M, Barnes J, Soot A, Sutcliffe J, Hayslett JP (1996) Outcome of pregnancy in women with chronic kidney disease: maternal and fetal outcomes. N Engl J Med 335:226–232

114. Bramham K, Briley AL, Seed PT et al (2011) Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. Reprod Sci 18:623–630

115. Alsuwaida A, Mousa D, Al-Harbi A et al (2011) Impact of early chronic kidney disease on maternal and fetal outcomes of pregnancy. J Matern Fetal Neonatal Med 24:1432–1436

116. Singh R, Prasad N, Banka A, Gupta A, Bhadauria D, Sharma RK, Kaul A (2015) Pregnancy in patients with chronic kidney disease: maternal and fetal outcomes. Indian J Nephrol 25(4):194–199

117. Feng Z, Minard C, Raghavan R (2015) Pregnancy outcomes in advanced kidney disease. Clin Nephrol 83(5):272–278

118. Kendrick J, Sharma S, Holmen J, Palit S, Nuccio E, Chonchol M (2015) Kidney disease and maternal and fetal outcomes in pregnancy. Am J Kidney Dis 66(1):55–59

119. Williams D, Davis J (2008) Chronic kidney disease in pregnancy. BJM 33:211–215

120. Williams D, Davis J (2008) Chronic kidney disease in pregnancy. BMJ 33:211–215

121. Wineruds CG, Glassock RJ (2009) Dissecting and refining the literature. J Assist Reprod Genet 28(4):351–353

122. Bramham K, Lightstone L (2012) Pre-pregnancy counseling for women with chronic kidney disease. J Nephrol 25(4):450–459

123. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV. 10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant 17(Suppl 4):50–55

124. McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL et al; Women’s Health Committee of the American Society of Transplantation (2005) Reproduction and transplantation: report on the AST consensus conference on reproductive issues and transplantation. Am J Transplant 5(7):1592–1599

125. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155

126. Knoll GA, Blydt-Hansen TD, Campbell P, Cantarovich M, Cole E, Fairhead T et al (2010) Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 56(2):219–246

127. Josephson MA, McKay DB (2011) Pregnancy and kidney transplantation. Semin Nephrol 31(1):100–110

128. Josephson MA, McKay DB (2013) Women and transplantation: fertility, sexuality, pregnancy, contraception. Adv Chronic Kidney Dis 20(5):433–440

129. Hold PM, Wong CF, Dhanda RK, Walkinshaw SA, Bakran A (2005) Successful renal transplantation during pregnancy. Am J Transplant 5(9):2315–2317

130. Vega J, Videla C, Santis O, Lira M, Goecke H (2012) Kidney transplantation during a twin pregnancy. Case report and review of the literature. CEN Case Rep 1(1):43–49

131. Imbasciati E, Tincani A, Gregorini G et al (2009) Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 24:519–525

132. Ma KK, Petroff MG, Coscia LA, Armenti VT, Adams Waldorf KM (2013) Complex chimerism: pregnancy after solid organ transplantation. Chimeraism 4(3):71–77

133. Porrett PM (2018) Biologic mechanisms and clinical consequences of pregnancy alloimmunization. Am J Transplant 18(5):1059–1067

134. Villie P, Dommergues M, Brocheriou I, Piccoli GB, Tourret J, Hertig A (2018) Why kidneys fail post-partum: a tubulocentric viewpoint. J Nephrol. https://doi.org/10.1007/s40602-018-0488-0. (Epub ahead of print)

135. Piccoli GB, Consiglio V, Deagostini MC et al (2011) The clinical and imaging presentation of acute “non-complicated” pyleonephritis: a new profile for an ancient disease. BMC Nephrol 12:68

136. Toffolo A, Ammenti A, Montini G (2012) Long-term clinical consequences of urinary tract infections during childhood: a review. Acta Paediatr 101(10):1018–1031

137. Fiocchi R, D’Elia E, Vittori C, Sebastiani R, Strobelt N, Eleftheriou G et al (2016) First Report of a successful pregnancy in an everolimus-treated heart-transplanted patient: neonatal disappearance of immunosuppressive drugs. Am J Transplant 16(4):1319–1322

138. Carta P, Caroti L, Zanazzi M (2012) Pregnancy in a kidney transplantation patient treated with everolimus. Am J Kidney Dis 60(2):329

139. Margoles HR, Gomez-Lobo V, Veis JH, Sherman MJ, Moore J Jr (2014) Successful maternal and fetal outcome in a kidney transplant patient with everolimus exposure throughout pregnancy: a case report. Transplant Proc 46(1):281–283

140. http://www.fda.gov. Accessed 8 Jan 2018

141. Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Ferrario G et al (2016) First Report of a successful pregnancy in an everolimus-treated heart-transplanted patient: neonatal disappearance of immunosuppressive drugs and reproduction. Arthritis Res Ther 8(3):209

142. Bar Oz B, Hackman R, Einarson T, Koren G (2001) Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71:1051–1055

143. Kainz A, Habaracz I, Cowlick IS et al (2000) Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 70:1718–1721

144. Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG et al (2013) Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 95:908–915

145. Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392

146. Sifontis NM, Coscia LA, Constantinescu S et al (2006) Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698–1702
Anderka MT, Lin AE, Abuelo DN et al (2009) Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 149A:1241–1248

Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, Biancone L (2018) Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol. https://doi.org/10.1007/s40620-018-0477-3

Framarino-dei-Malatesta M, Derme M, Manzia TM et al (2013) Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. Expert Rev Clin Immunol 9:781–89

Blume C, Pischke S, von Versen-Höynck F, Günter HH, Gross MM (2014) Pregnancies in liver and kidney transplant recipients: a review of the current literature and recommendation. Best Pract Res Clin Gastroenterol 28(8):1123–1136

Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M (2017) Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16–21

Paziana K, Del Monaco M, Manzia TM, Moritz M, Keller M, Armenti V, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti V (2013) Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 36:416–438

Kalliala I, Markozannes G, Günter MJ, Paraskevaidis E, Gabra H, Mitra A, Terzidou V, Bennett P, Martin-Hirsch P, Tsilidis KK, Kyrgiou M (2017) Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ 359:j4511

Gutaj P, Zawiejska A, Mantaj U, Wender-Ożegowska E (2016) Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet 60:16–21

Magee LA, Pels A, Helewa M et al (2014) Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 36:416–438

Kalliala I, Markozannes G, Günter MJ, Paraskevaidis E, Gabra H, Mitra A, Terzidou V, Bennett P, Martin-Hirsch P, Tsilidis KK, Kyrgiou M (2017) Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ 359:j4511

Gutaj P, Zawiejska A, Mantaj U, Wender-Ożegowska E (2017) Determinants of preeclampsia in women with type 1 diabetes. Acta Diabetol 54(12):1115–1121

Blázquez A, García D, Rodríguez A, Vassena R, Figueras F, Verdejo P, Puig A, Gómez A, Palaci A, Rodríguez S, Pepe L, Barja R, Vázquez M, Martín J (2017) Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16–21

Wise J (2015) Tight blood pressure control during pregnancy offers no clear benefits, study finds. BMJ 350:h549

Magee LA; CHIPS Study Group, von Dadelszen P et al (2016) Antihypertensive drug receptor blocker therapy during pregnancy: setting the record straight. Nat Rev Cardiol 12(4):196

Lewis G, Maxwell AP (2014) Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Diabetologia 57(5):1082–1083

Cooper HO, Hernandez-Diaz S, Arbogast PG et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443–2451

Li DK, Yang C, Andrade S, Tavares V, Ferber JR (2011) Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 343:d5931

Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS (2013) Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy 33:476–482

Al-Balas M, Bozzo P, Einaron A (2009) Use of diuretics during pregnancy. Can Fam Physician 55(1):44–45

Parr M, Rodrigo R, Barja P, Bosco C, Fernández V, Muñoz H, Soto-Chacón E (2005) Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 193(4):1486–1491

Papageorghiou AT, Roberts N (2005) Uterine artery Doppler screening for adverse pregnancy outcome. Curr Opin Obstet Gynecol 17(6):584–590

Piccoli GB, Gaglioti P, Attini R, Parisi S, Bossotti C, Olearo E et al (2013) Pre-eclampsia or chronic kidney disease? The flow hypothesis. Nephrol Dial Transplant 28(5):1199–206

Bar J, Ben-Rafael Z, Padon A, Orvieto R, Boner G, Hod M (2000) Prediction of pregnancy outcome in subgroups of women with renal disease. Clin Nephrol 53(6):437–444

Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7):672–683

Zeisler H, Llurba E, Chantreire F, Vatish M, Staff AC, Sennström M et al (2016) Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374(1):13–22

Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE (2007) Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 197(3):244.e1–8

Kleinrouweiler CE, Wiegnerick MM, Ris-Stalpers C et al (2012) EBMT CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble FMS-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 119(7):778–787

Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the US Preventive Services Task Force (2014) US Preventive Services
186. Roberge S, Villa P, Nicolaides K, Gigüère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E (2012) Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 31(3):141–146

187. Bujold E, Roberge S, Lacasse Y et al (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2 Pt 1):402–414

188. Roberge S, Gigüère Y, Villa P et al (2012) Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 29(7):551–556

189. Comorarasamy A, Honest H, Papaioannou S, Gee H, Khan KS (2003) Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 101:1319–1332

190. Rolnik DL, Wright D, Poon LCY et al (2017) ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 50:492–495

191. Roberge S, Bujold E, Nicolaides KH (2018) Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol 218(5):483–489

192. Roberge S, Bujold E, Nicolaides KH (2018) Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol 218(3):287–293.e1

193. Boldt J (2010) Use of albumin: an update. Br J Anaesth 104:276e84

194. Piccoli GB, Attini R, Vasario E et al (2011) Vegetarian supplemented low-protein diets. A safe option for pregnant CKD patients: report of 12 pregnancies in 11 patients. Nephrol Dial Transplant 26(1):196–205

195. Piccoli GB, Leone F, Attini R et al (2014) Association of low-protein supplemented diets with fetal growth in pregnant women with CKD. Clin J Am Soc Nephrol 9(5):864–873

196. Stratta P, Canavese C, Giacchino F, Mesiano P, Quaglia M, Rossetti M (2003) Pregnancy in kidney transplantation: satisfactory outcomes and harsh realities. J Nephrol 16(6):792–806

197. Grandjean H, Larroque D, Levi S (1999) The performance of routine ultrasonographic screening of pregnancies in the Eurofetus Study. Am J Obstet Gynecol 181(2):446–454

198. Krajewski CM, Geetha D, Gomez-Lobo V (2013) Contraceptive options for women with a history of solid-organ transplantation. Transplantation 95(10):1183–1186

199. Paulen ME, Folger SG, Curtis KM, Jamieson DJ (2010) Contraceptive use among solid organ transplant patients: a systematic review. Contraception 82(1):102–112

200. Xu L, Yang Y, Shi JG et al (2011) Unwanted pregnancy among Chinese renal transplant recipients. Eur J Contracept Reprod Health Care 16(4):270–276

201. Ramhendar T, Byrne P (2012) Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception 86(3):288–289

202. Paternoster DM, Riboni F, Bertolino M et al (2010) The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results. Transplant Proc 42(4):1162–1165

203. Skannal DG, Miodovnik M, Dungy-Poythress LJ, First MR (1996) Successful pregnancy after combined renal-pancreas transplantation: a case report and literature review. Am J Perinatol 13:383–387

204. Grenfell A, Bewick M, Brudnell JM, Carr JV, Parsons V, Snowden S, Watkins PJ (1986) Diabetic pregnancy following renal transplantation. Diabet Med 3:177–179

205. Tydén G, Brattström C, Björkman U, Landgraf R, Baltzer J, Hillebrand G, Land W, Calne R, Brons IG, Squifflet JP (1989) Pregnancy after combined pancreas-kidney transplantation. Diabetes 38(Suppl 1):43–45

206. Armenti VT, Radomski JS, Moritz MJ, Gaughan WH, Hecker WP, Lavelanet A, McGrory CH, Coscia LA (2004) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transplant 103–114

207. Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ (2007) Pregnancy after organ transplantation: a report from the UK transplant pregnancy registry. Transplantation 83:1301–1307

Affiliations

Gianfranca Cabiddu1 · Donatella Spotti2 · Giuseppe Gernone3 · Domenico Santoro4 · Gabriella Moroni5 · Gina Gregorini6 · Franca Giacchino7 · Rossella Attini8 · Monica Limardo9 · Linda Gammaro10 · Tullia Todros8 · Giorgina Barbara Piccoli11,12 on behalf of The Kidney and Pregnancy Study Group of the Italian Society of Nephrology

1 Azienda Ospedaliera Brotzu, Cagliari, Italy
2 IRCCS San Raffaele Hospital, Milan, Italy
3 Santa Maria Degli Angeli Hospital, Putignano, Italy
4 Azienda Ospedaliera Universitaria G. Martino, Messina, Italy
5 Fondazione Ca’ Granda Ospedale Maggiore, Milan, Italy
6 Spedali Civili di Brescia, Brescia, Italy
7 Ospedale d’Ivrea, Ivrea, Italy
8 Department of Surgery, Università di Torino, Turin, Italy
9 Azienda Ospedaliera della Provincia di Lecco, Lecco, Italy
10 Ospedale Fracastoro, San Bonifacio, Italy
11 Department of Clinical and Biological Sciences, Università di Torino, Turin, Italy
12 Centre Hospitalier Le Mans, Le Mans, France